Literature DB >> 20238407

Combined MELD and blood lipid level in evaluating the prognosis of decompensated cirrhosis.

Ming Jiang1, Fei Liu, Wu-Jun Xiong, Lan Zhong, Wen Xu, Fei Xu, Yan-Bing Liu.   

Abstract

AIM: To evaluate the prognostic value of the combined model for end-stage liver disease (MELD) and blood lipid level in patients with decompensated cirrhosis.
METHODS: A total of 198 patients with decompensated cirrhosis were enrolled into the study. The values of triglyceride (TG), cholesterol (TC), high density lipoproteins (HDL) and low density lipoprotein (LDL) of each patient on the first day of admission were retrieved from the medical records, and MELD was calculated. All the patients were followed up for 1 year. The relationship between the change of blood lipid level and the value of MELD score was studied by analysis of variance. The prognostic factors were screened by multivariate Cox proportional hazard model. Draw Kaplan-Meier survival curves were drawn.
RESULTS: Forty-five patients died within 3 mo and 83 patients died within 1 year. The levels of TG, TC, HDL and LDL of the death group were all lower than those of the survivors. The serum TG, TC, HDL and LDL levels were lowered with the increase of the MELD score. Multivariate Cox proportional hazard model showed that MELD >or= 18 and TC <or= 2.8 mmol/L were independent risk factors for prognosis of decompensated cirrhosis. Survival analysis showed that MELD >or= 18 combined with TC <or= 2.8 mmol/L can clearly discriminate between the patients who would survive and die in 1 year.
CONCLUSION: MELD >or= 18 and TC <or= 2.8 mmol/L are two important indexes to predict the prognosis of patients with decompensated cirrhosis. Their combination can effectively predict the long-term prognosis of patients with decompensated cirrhosis. 2010 Baishideng. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20238407      PMCID: PMC2842532          DOI: 10.3748/wjg.v16.i11.1397

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  15 in total

1.  Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death.

Authors:  Douglas M Heuman; Souheil G Abou-Assi; Adil Habib; Leslie M Williams; R Todd Stravitz; Arun J Sanyal; Robert A Fisher; Anastasios A Mihas
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

2.  MELD: the holy grail of organ allocation?

Authors:  Richard B Freeman
Journal:  J Hepatol       Date:  2005-01       Impact factor: 25.083

Review 3.  Development of the allocation system for deceased donor liver transplantation.

Authors:  John M Coombes; James F Trotter
Journal:  Clin Med Res       Date:  2005-05

4.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.

Authors:  M Malinchoc; P S Kamath; F D Gordon; C J Peine; J Rank; P C ter Borg
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

5.  High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics.

Authors:  Adil Habib; Anastasios A Mihas; Souheil G Abou-Assi; Leslie M Williams; Edith Gavis; W Michael Pandak; Douglas M Heuman
Journal:  Clin Gastroenterol Hepatol       Date:  2005-03       Impact factor: 11.382

6.  MELD accurately predicts mortality in patients with alcoholic hepatitis.

Authors:  Winston Dunn; Laith H Jamil; Larry S Brown; Russell H Wiesner; W Ray Kim; K V Narayanan Menon; Michael Malinchoc; Patrick S Kamath; Vijay Shah
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

7.  Prognostic factors for chronic severe hepatitis and construction of a prognostic model.

Authors:  Qian Li; Gui-Yu Yuan; Ke-Cheng Tang; Guo-Wang Liu; Rui Wang; Wu-Kui Cao
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2008-02

8.  Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt.

Authors:  B Angermayr; M Cejna; F Karnel; M Gschwantler; F Koenig; J Pidlich; H Mendel; L Pichler; M Wichlas; A Kreil; M Schmid; A Ferlitsch; E Lipinski; H Brunner; J Lammer; P Ferenci; A Gangl; M Peck-Radosavljevic
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

Review 9.  Acute liver failure in the United States.

Authors:  William M Lee
Journal:  Semin Liver Dis       Date:  2003-08       Impact factor: 6.115

10.  Human serum fetuin A/alpha2HS-glycoprotein level is associated with long-term survival in patients with alcoholic liver cirrhosis, comparison with the Child-Pugh and MELD scores.

Authors:  László Kalabay; László Gráf; Krisztián Vörös; László Jakab; Zsuzsa Benko; László Telegdy; Béla Fekete; Zoltán Prohászka; George Füst
Journal:  BMC Gastroenterol       Date:  2007-03-29       Impact factor: 3.067

View more
  10 in total

Review 1.  Abnormalities of Lipoprotein Levels in Liver Cirrhosis: Clinical Relevance.

Authors:  Graziella Privitera; Luisa Spadaro; Simona Marchisello; Giuseppe Fede; Francesco Purrello
Journal:  Dig Dis Sci       Date:  2017-11-25       Impact factor: 3.199

Review 2.  Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS.

Authors:  Mohamad R Al Sibae; Mitchell S Cappell
Journal:  Dig Dis Sci       Date:  2010-09-16       Impact factor: 3.199

Review 3.  Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications.

Authors:  Katriina Nemes; Fredrik Åberg; Helena Gylling; Helena Isoniemi
Journal:  World J Hepatol       Date:  2016-08-08

4.  Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma.

Authors:  Mario Uccello; Giulia Malaguarnera; Elisa M Pelligra; Antonio Biondi; Francesco Basile; Massimo Motta
Journal:  Indian J Med Paediatr Oncol       Date:  2011-04

5.  Lipid profile in cirrhotic patients and its relation to clinical outcome.

Authors:  Laura Boemeke; Lilian Bassani; Cláudio Augusto Marroni; Catarina Bertaso Andreatta Gottschall
Journal:  Arq Bras Cir Dig       Date:  2015 Apr-Jun

6.  Metabolomic and transcriptomic profiling of hepatocellular carcinomas in Hras12V transgenic mice.

Authors:  Tingting Fan; Zhuona Rong; Jianyi Dong; Juan Li; Kangwei Wang; Xinxin Wang; Huiling Li; Jun Chen; Fujin Wang; Jingyu Wang; Aiguo Wang
Journal:  Cancer Med       Date:  2017-09-21       Impact factor: 4.452

7.  An observational study on the effect of hypercholesterolemia developed after living donor liver transplantation on cardiac event and graft failure.

Authors:  Jungchan Park; Seung-Hwa Lee; Sangbin Han; Ah Ran Oh; Suk-Koo Lee; Gyu-Seong Choi; Myung Soo Park; Keumhee Carriere; Joonghyun Ahn; Gaab Soo Kim
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

8.  Fontan-Associated Dyslipidemia.

Authors:  Adam M Lubert; Tarek Alsaied; Joseph J Palermo; Nadeem Anwar; Elaine M Urbina; Nicole M Brown; Craig Alexander; Hassan Almeneisi; Fred Wu; Andrew R Leventhal; Nael Aldweib; Michael Mendelson; Alexander R Opotowsky
Journal:  J Am Heart Assoc       Date:  2021-03-31       Impact factor: 5.501

9.  Serum Ceramide Species Are Associated with Liver Cirrhosis and Viral Genotype in Patients with Hepatitis C Infection.

Authors:  Marcus Höring; Georg Peschel; Jonathan Grimm; Sabrina Krautbauer; Martina Müller; Kilian Weigand; Gerhard Liebisch; Christa Buechler
Journal:  Int J Mol Sci       Date:  2022-08-29       Impact factor: 6.208

10.  Body mass index and cholesterol level predict surgical outcome in patients with hepatocellular carcinoma in Taiwan - a cohort study.

Authors:  Ya-Ling Lee; Wan-Chun Li; Tung-Hu Tsai; Hsin-Yu Chiang; Chin-Tsung Ting
Journal:  Oncotarget       Date:  2016-04-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.